PT. RICHMOND, Calif., Aug. 2 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).
Advertisement
Conference Call Information
A simultaneous web cast of the conference call will be available on the Investor Relations section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.
Advertisement
A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.
Date: Monday, August 3, 2009 Time: 8:30 a.m. ET Dial-in (U.S.): 877-545-1490 Dial-in (International): 719-325-4864
SOURCE Transcept Pharmaceuticals, Inc.
